Publications by authors named "M Agamennone"

Historically, appendectomy was the standard treatment for acute appendicitis (AA). Recently, interest has grown in conservative management of uncomplicated AA (UA). This study compared outcomes between non-operative management (NOM) and appendectomy, exploring preoperative factors to guide optimal UA management.

View Article and Find Full Text PDF
Article Synopsis
  • Nearly half of the global population is affected by an infection, with current treatments involving antibiotics and proton pump inhibitors; however, rising antimicrobial resistance remains a major issue.
  • Phenolic monoterpenes like eugenol, vanillin, carvacrol, and thymol are of interest for their biological activities and potential for easy modifications, leading to the creation of mono- and bis-azo derivatives through aryl diazotization.
  • The synthesized compounds were tested against various bacterial strains, revealing some effective inhibitors and subsequently underwent cytotoxicity evaluations and target investigations using structure-based docking calculations on key pharmacological targets.
View Article and Find Full Text PDF

Ciprofloxacin (CPX) is one of the most employed antibiotics in clinics to date. However, the rise of drug-resistant bacteria is dramatically impairing its efficacy, especially against life-threatening pathogens, such as . This Gram-negative bacterium is an opportunistic pathogen, often infecting immuno-compromised patients with severe or fatal outcomes.

View Article and Find Full Text PDF

In recent years, continuous progress has been made in the development of new anticancer drugs, and several compounds (small molecules, engineered antibodies, immunomodulators, etc [...

View Article and Find Full Text PDF

Immunotherapy has marked a revolution in cancer therapy. The most extensively studied target in this field is represented by the protein-protein interaction between PD-1 and its ligand, PD-L1. The promising results obtained with the clinical use of monoclonal antibodies (mAbs) directed against both PD-1 and PD-L1 have prompted the search for small-molecule binders capable of disrupting the protein-protein contact and overcoming the limitations presented by mAbs.

View Article and Find Full Text PDF